ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0942

Use of Medical Cannabis by Patients with Fibromyalgia: A Prospective Cross-sectional Study

Mary-Ann Fitzcharles1, Emmanouil Rampakakis2, Yoram Shir1, John Sampalis2, Martin Cohen1, Michael Starr1 and Winfried Häuser3, 1McGill University, montreal, Canada, 2JSS Medical Research, St-Laurent, QC, Canada, 3Technische Universität München, Munich, Germany

Meeting: ACR Convergence 2020

Keywords: fibromyalgia, pain, Therapy, alternative

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Fibromyalgia & Other Clinical Pain Syndromes (0940–0944)

Session Type: Abstract Session

Session Time: 10:00AM-10:50AM

Background/Purpose: Treatment strategies for chronic widespread pain (CWP)/fibromyalgia (FM) are imperfect with only a modest effect from medications. Due to the many symptoms experienced by patient, including pain, sleep disturbance and often mental health complaints, an agent that could address multiple symptoms would be ideal. Cannabinoids may have potential to fill this gap. In the setting of recreational legalization of cannabis in Canada, patients now have easier access and may be self-medicating with cannabis. We have examined the prevalence and characteristics of use in FM patients.

Methods: During a two-month period (April-May 2019), consecutive patients attending an academic, community-based rheumatology clinic staffed by 3 rheumatologists participated in an onsite survey comprising 2 questionnaires: 1) demographic and disease information completed by the rheumatologist, 2) patient anonymous questionnaire of health status, cannabis use (recreational and/or medicinal) and characteristics of use.

Results: In a cohort of 1000 rheumatology attendees (73% females; mean age 64 ± 14 yrs), 117 (11.7%) were diagnosed with FM. Medical cannabis (MC) had ever been used by 12.6% (95% CI: 10.7%-14.8%) of the whole cohort, with half continuing use for mostly pain relief. Of the 117 FM patients, 28 (24%) had ever used medical cannabis (95% CI: 16.5%-32.7%), with 16 (57%) continuing use. Users vs. non users were more likely to be younger, 53 vs.58 yrs (p=0.072) and unemployed or disabled 39% vs. 17% (p=0.019), and used more medication types for symptom control (p=0.013), but symptom severity parameters did not differ between groups Table 1. Users were more likely to be past and current cigarette smokers, and previous or current recreational cannabis users. Some comorbid rheumatic condition was present in 82 (70.1%), with 35 (30%) diagnosed with an inflammatory condition. Almost half of patients with FM comorbid with ankylosing spondylitis had used medical cannabis. Symptom relief (VAS, 1-10) was 7.0 ±2.3.

Conclusion: FM patients, including those with comorbid rheumatic conditions, have commonly used medical cannabis, with more than half continuing use. Although symptom severity parameters were similar for users vs. nonusers, symptom relief was reported to be moderately good.  Cigarette smoking and recreational cannabis use may play a facilitatory role in medical cannabis use in FM. Adjunctive medical cannabis may be a treatment consideration for patients with CWP, either as a unique diagnosis of FM or comorbid with inflammatory arthritis.

Table 1. Demographic and Disease Related information for fibromyalgia patients (part 1)

Table 1. Demographic and Disease Related information for fibromyalgia patients (part 2)

Table 1. Demographic and Disease Related information for fibromyalgia patients (part 3)


Disclosure: M. Fitzcharles, None; E. Rampakakis, None; Y. Shir, None; J. Sampalis, None; M. Cohen, None; M. Starr, None; W. Häuser, None.

To cite this abstract in AMA style:

Fitzcharles M, Rampakakis E, Shir Y, Sampalis J, Cohen M, Starr M, Häuser W. Use of Medical Cannabis by Patients with Fibromyalgia: A Prospective Cross-sectional Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/use-of-medical-cannabis-by-patients-with-fibromyalgia-a-prospective-cross-sectional-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-medical-cannabis-by-patients-with-fibromyalgia-a-prospective-cross-sectional-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology